Peptide inhibitors of IL-10 signaling, either directed to IL-10 or the IL-10R, have advantages such as lower manufacturing cost, higher activity per unit mass, greater stability for storage, better organ penetration, and the possibility of sequence modification to improve activity, half-life, and specificity, and they might be useful in cancer treatment [110]. This evidence concerns the gene IL10 and cancer.